Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pliant Therapeutics, Inc. - Common Stock (NQ: PLRX ) 13.56 -0.47 (-3.35%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 364,368 Open 13.98 Bid (Size) 11.78 (1) Ask (Size) 14.25 (11) Prev. Close 14.03 Today's Range 13.48 - 14.23 52wk Range 10.22 - 19.62 Shares Outstanding 35,937,937 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Thursday's Pre-Market Session December 19, 2024 Via Benzinga Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket December 13, 2024 Via Benzinga Performance YTD -24.50% -24.50% 1 Month +0.22% +0.22% 3 Month +19.89% +19.89% 6 Month +26.14% +26.14% 1 Year -29.04% -29.04% More News Read More Pliant Therapeutics to Participate in Upcoming Investor Events November 21, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 November 18, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings May 07, 2024 Via Benzinga Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results November 07, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in the Stifel Healthcare Conference November 06, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 October 17, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs October 01, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 30, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer September 24, 2024 From Aligos Therapeutics Via GlobeNewswire Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024 September 10, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Events August 28, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024 August 26, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024 August 07, 2024 Via InvestorPlace Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results August 07, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference August 06, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures July 15, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 Via InvestorPlace Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors June 13, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 12, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ June 06, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference May 21, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients May 14, 2024 Via Benzinga Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis May 14, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.